ArticleThe Journal of investigative dermatology2013
Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma.
Article in The Journal of investigative dermatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 4 syntheses or guidelines pooled it, 179 citations in OpenAlex.
- Swiss Recommendations for Cutaneous Basal Cell Carcinoma.Dermatology (Basel, Switzerland) · 2023Guideline
- Incomplete Excision of Cutaneous Squamous Cell Carcinoma; Systematic Review of the Literature.Acta dermato-venereologica · 2020Pooled it
- Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies.BMJ (Clinical research ed.) · 2013Pooled it
- Risk of Skin Cancers in Older Persons Living With HIV: A Systematic Review.The Journal of the Association of Nurses in AIDS Care : JANACPooled it
- Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome.Cancer prevention research (Philadelphia, Pa.) · 2014Trial
- Reflectance Confocal Microscopy-Optical Coherence Tomography-Guided Laser Ablation of Low-Risk Basal Cell Carcinoma: A Long-Term Prospective Follow-Up Study.Lasers in surgery and medicine · 2026Article
- Long-term Recurrence after Curettage ± Electrodesiccation for Basal Cell Carcinoma: A Nationwide Cohort Study of 47,358 Tumours from Dermatology Practices.Acta dermato-venereologica · 2026Article
- Mohs Surgery vs. Wide Local Excision for Non-Melanoma Skin Cancer: Comparing Recurrence Rates, Economic Value, and Aesthetic Outcomes.Journal of cancer science and clinical therapeutics · 2026Article
- The Epidemiological and Histopathological Profiling of Basal Cell Carcinoma: Insights from a 4-Year Institutional Cohort in a Romanian Clinical County Hospital.Diagnostics (Basel, Switzerland) · 2025Article
- The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies.Current treatment options in oncology · 2025Review
- A Review of Neoadjuvant PD-1 Inhibitors in the Setting of Cutaneous Malignancies.The Journal of clinical and aesthetic dermatology · 2025Review
- Squamous Cell Carcinoma of the Nail Bed.The Permanente journal · 2024Article
- Is a 3 mm Surgical Margin Safe for Basal Cell Carcinoma in the Head and Neck that is Less than 2 cm, Considering Different Risk Factors?Archives of plastic surgery · 2024Article
- Article
- Review
- Global burden and prediction study of cutaneous squamous cell carcinoma from 1990 to 2030: A systematic analysis and comparison with China.Journal of global health · 2024Article
- Treatment of Basal Cell Carcinoma of the Lower Eyelid With High-Dose-Rate Brachytherapy.Cureus · 2024Article
- Multicenter Retrospective Andalusian Study of the Use of Sonidegib for the Treatment of Local Advanced Basal Cell Carcinoma in Real Clinical Practice.Journal of clinical medicine · 2023Article
- Clinicopathological features of patients with wide local excision of eyelid malignant neoplasms: a more than five years retrospective study from China.BMC ophthalmology · 2022Article
- Systemic Photodynamic Therapy With Chlorine e6 as a Photosensitizer for the Treatment of Nodular BCC: A Case Report.Journal of lasers in medical sciences · 2022Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
For most cutaneous basal cell and squamous cell carcinomas (nonmelanoma skin cancers (NMSCs)), data are insufficient to permit evidence-based choices among treatments. To compare tumor recurrence after treatments, we conducted a prospective cohort study of consecutive patients with primary NMSCs treated with the most common treatments, in two practices in 1999-2000. Recurrence was determined from medical records by observers blinded to treatment type. Follow-up was available for 1,174 patients with 1,488 tumors (93.8%) at median 7.4 years; of these tumors, 24.3% (N=361) were treated with destruction with electrodessication/curettage, 38.3% (N=571) with excision, and 37.4% (N=556) with histologically guided serial excision (Mohs surgery). The overall 5-year tumor recurrence rate (95% confidence interval) was 3.3% (2.3, 4.4). Unadjusted recurrence rates did not differ after treatments: 4.9% (2.3, 7.4) after destruction, 3.5% (1.8, 5.2) after excision, and 2.1% (0.6, 3.5) after Mohs surgery (P=0.26), and no difference was seen after adjustment for risk factors. In tumors treated only with excision or Mohs surgery, the hazard of recurrence was not significantly different, even after adjustment for propensity for treatment with Mohs surgery. These data indicate that common treatments for NMSCs were at least 95% effective, and further studies are needed to guide therapeutic choices for different clinical subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.